Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it has obtained marketing authorization from the Ministry of Food and Drug Safety (MFDS) of South Korea for Eydenzelt (CT-P42), a biosimilar to Eylea, covering all approved indications of the reference drug, including neovascular (wet) age-related macular degeneration and diabetic macular edema. 📊…

Read More “[Disclosure] Celltrion (068270) – Marketing Authorization Granted by South Korean MFDS for Eydenzelt (CT-P42, Eylea Biosimilar) / 2024-05-30” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics announced a voluntary disclosure regarding the official publication of its ‘Samsung Biologics ESG Report 2024’, which highlights its economic, environmental, and social performance for 2023 alongside three-year non-financial trends. 📊 [Key Disclosure Details & Summary Statistics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Reviewing…

Read More “[Disclosure] Samsung Biologics (207940) – Matters Related to Sustainability Report (Voluntary Disclosure) / 2024-05-30” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics announced an amendment extending the non-disclosure deadline for the counterparty of a contract manufacturing LOI signed with a European pharmaceutical company to June 30, 2024, in consultation with the client. 📊 [Key Disclosure Details & Summary Statistics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] Samsung Biologics (207940) – Major Management Matters (Correction) / 2024-05-30” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it has obtained final marketing authorization from the European Commission (EC) for Omlyclo (CT-P39), a biosimilar to Xolair, covering 30 European countries for all approved indications of the reference drug. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Read More “[Disclosure] Celltrion (068270) – Final Marketing Authorization Granted by European Commission (EC) for Omlyclo (CT-P39, Xolair Biosimilar) / 2024-05-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following the exercise of stock options, 136,700 new common shares will be issued and additionally listed on May 22, 2024. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Why Verifying Additional Listing and Changes in Total Shares Outstanding Is Necessary…

Read More “[Disclosure] ALTEOGEN (196170) – Additional Listing (Exercise of Stock Options) / 2024-05-17” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen will hold an Investor Relations (IR) conference for major domestic and foreign institutional investors at Shinhan Securities headquarters on May 16, 2024, to enhance investor understanding. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Why Verifying IR Material Release…

Read More “[Disclosure] ALTEOGEN (196170) – Holding of Investor Relations (IR) Session / 2024-05-10” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported its provisional Q1 2024 separate financial results, recording revenue of approximately KRW 638.2B and operating profit of approximately KRW 28.8B, representing a 102.70% QoQ increase in revenue. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Comparison Between Separate…

Read More “[Disclosure] Celltrion (068270) – Provisional Sales Results / 2024-05-09” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported its provisional Q1 2024 consolidated financial results, recording revenue of approximately KRW 737.0B and operating profit of approximately KRW 15.4B, representing a 92.63% QoQ increase in revenue. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Final…

Read More “[Disclosure] Celltrion (068270) – Provisional Sales Results (Consolidated Financial Statements) / 2024-05-09” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced the additional listing of 63,385 new common shares on May 14, 2024, issued following the exercise of stock options. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Total Issued Shares and Stock Quantity Changes Post-Listing This…

Read More “[Disclosure] Celltrion (068270) – Additional Listing (Stock Option Exercise) / 2024-05-09” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has revised its pharmaceutical contract manufacturing agreement with Eli Lilly, increasing the total contract value by KRW 256.2B from KRW 327.8B to KRW 584.1B upon customer request. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Revenue Recognition…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Sales / Supply Contract / 2024-05-08” »